Taiwan and Singapore back NSV’s US$53M bet on Asia’s biotech pipeline
Raising a debut fund in 2026 is hard. Raising one for biotech, a sector investors have spent four years avoiding, is harder still. NeoSci Ventures (NSV) says it has done it anyway. The Singapore-, Taiwan- and US-based venture builder has announced a first close of SGD70 million (US$53 million) for its inaugural institutional fund. The […] The post Taiwan and Singapore back NSV’s US$53M bet on…
Singapore and Taiwan have backed NeoSci Ventures (NSV) with SGD70 million (US$53 million) for its inaugural fund. NSV aims to invest in therapeutics and companies at the intersection of biology, AI, data, and scientific tools across the US and Asia. The venture builder, founded by Singaporean Daphne Teo and American Timothy Lu, sees strong investor support despite a challenging environment for biotech investments.
NSV's approach differs from traditional venture capital – it actively builds companies using its own people and expertise. With a track record of helping companies secure billions in funding and achieve successful exits, Teo and Lu believe they can spot promising opportunities early and turn them into market-ready products.
Written by urgent.news from e27's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
